Ganoderma lucidum, a renowned medicinal mushroom, produces a diverse array of triterpenoids with pharmacological potential. Yet, the underlying biosynthetic logic of these specialized metabolites, particularly the type II ganoderic acids (TIIGAs), has remained opaque, hindering both mechanistic understanding and biotechnological exploitation.
Researchers systematically reconstructed the TIIGA biosynthetic pathway, resolving long-standing gaps in enzyme function and pathway organization. Most notably, they identified CYP512W6, a cytochrome P450 hydroxylase uniquely responsible for catalysis at the C22 position. Structural and mutagenesis analyses revealed that non-conserved residues (V105, M365) are critical for enzymatic activity, underscoring its evolutionary distinctiveness.
Equally striking was the discovery of GlAT, a bifunctional acetyltransferase with unprecedented activity at both C15 and C22. Such dual functionality had not been observed in triterpenoid biosynthesis and expands the enzymatic toolkit for tailoring complex scaffolds. By temporally regulating enzyme expression in engineered yeast hosts, the team overcame metabolic bottlenecks, achieving de novo synthesis of over 30 TIIGAs at titers vastly exceeding those from natural cultivation.
The implications extend beyond Ganoderma metabolites. This work illustrates the potential of network reprogramming, strategically combining endogenous and heterologous enzymes, then regulating their sequence of activity, to unlock otherwise inaccessible chemical diversity. Furthermore, insights into catalytic mechanisms provide a foundation for rational protein engineering, promising greater control over substrate specificity and flux distribution.
The study positions medicinal mushrooms as tractable platforms for synthetic biology, opening avenues for scalable production of pharmacologically active triterpenoids. In doing so, it bridges traditional natural product discovery with modern metabolic engineering, setting the stage for functional food development and the next generation of mushroom-derived therapeutics.